Kidney Fibrosis Treatment Market Outlook Showing Demand Growth Across 2026–2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Kidney Fibrosis Treatment Market Over The 2026–2030 Period?

The kidney fibrosis treatment market size has experienced strong expansion in recent years. It is projected to increase from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The market’s growth during the historic period was primarily driven by factors such as the rising prevalence of chronic kidney disease, the limited effectiveness of traditional therapies, the increased adoption of ACE inhibitors and ARBs, the growing healthcare burden associated with renal failure, and the expansion of nephrology care services.

The market for kidney fibrosis treatments is projected to experience substantial growth over the coming years, anticipated to reach $8.84 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.8%. Key factors driving this expansion during the forecast period include progress in targeted antifibrotic therapies, a rising elderly demographic affected by CKD, the wider integration of precision medicine within nephrology, increased funding for renal research, and enhanced early detection of kidney disease. Significant trends expected during this period involve a heightened emphasis on developing antifibrotic drugs, a greater reliance on combination treatments for CKD, increased exploration into stem cell and regenerative treatments, the proliferation of tools for early diagnosis and monitoring, and an uptick in clinical trials aimed at renal fibrosis pathways.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

What Underlying Factors Are Accelerating The Growth Of The Kidney Fibrosis Treatment Market?

The future expansion of the kidney fibrosis treatment market is anticipated to be fueled by the growing occurrence of chronic kidney diseases. Chronic Kidney Disease (CKD) involves a progressive decline in kidney function over time, frequently caused by conditions like diabetes or high blood pressure, leading to the buildup of metabolic waste in the body. This surge in CKD prevalence is primarily attributed to the escalating rates of diabetes, a condition that harms renal blood vessels and compromises their filtration capacity. Kidney fibrosis treatment provides benefits to CKD patients by addressing the scarring of kidney tissue, alleviating inflammation, and decelerating the advance of kidney damage, thereby sustaining kidney function. For example, data from Hamadan University of Medical Sciences, an Iran-based university, projects that by 2030, the worldwide incidence of newly diagnosed chronic kidney diseases will reach 25.06 million, as reported in July 2025. Consequently, the rising occurrence of chronic kidney diseases is a key factor propelling the expansion of the kidney fibrosis treatment market.

How Is The Kidney Fibrosis Treatment Market Segmented Across Key Categories?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Which Upcoming Trends Are Expected To Influence The Kidney Fibrosis Treatment Market?

Major companies operating in the kidney fibrosis treatment market are increasingly focusing on specialized ileal-release immunomodulatory therapies. NEFECON exemplifies this trend, functioning as an oral delayed-release budesonide capsule that delivers the drug precisely to the distal ileum. This mechanism helps to modulate gut-associated B-cells and reduce the production of pathogenic IgA, thereby slowing the progression of kidney fibrosis in patients with IgA nephropathy. For example, Everest Medicines, a China-based biopharmaceutical company, launched NEFECON in June 2024. The therapy features an enteric-coated, delayed-release formulation to minimize systemic steroid exposure, directly targets mucosal B-cells in the gut to address the root cause of IgA nephropathy, and has shown significant potential in reducing kidney function decline.

Who Are The Dominant Players Shaping The Kidney Fibrosis Treatment Market Landscape?

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Read the full kidney fibrosis treatment market report here:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Region Is Projected To Dominate The Kidney Fibrosis Treatment Market During The Forecast Period?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Kidney Fibrosis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2026, By The Business Research Company

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Late Stage Chronic Kidney Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795